The goal of the POETRY Registry is to determine whether data from Pharmacogenomic (PGx) Testing for elderly and disabled patients can help physicians manage patient medication regimens and assess if the testing has an effect on reducing adverse drug events, hospitalizations, and emergency department visits.

The way an individual processes or metabolizes a drug is in part determined by their genes, and there is known to be genetic variation from one human to another. The study of the way in which genes affect an individual's response to drugs is known as "Pharmacogenomics."

Inclusion Criteria:

• Subject underwent PGx testing for the alleles appropriate to the target drugs within the prior 90 days ('index PGx test')
• Males and females aged ≥65 years or male and females aged ≥18 years who have a disability
• Subject is able and willing to provide written informed consent
• Subject was receiving at least one medication known to be associated with allelic variation at the time of the index PGx test, including over-the-counter medications
• Subject has a history of at least one target drug-related adverse event (TDAE) over the 12-month period preceding receipt of PGx test results, or has experienced inadequate efficacy from a target drug

Exclusion Criteria:

• Subject is currently hospitalized
• Subject's medical and medication history is unavailable over the 90-day period preceding the receipt of PGx test results
• Subject is unable to provide an accurate history due to mental incapacity
• Subject is known to have undergone prior PGx testing for genes specific to the target drug(s), exclusive of the PGx test relating to this Registry

Subjects aged 65 and above or subjects aged 18 and above who have a disability will be eligible for inclusion in the study if they are receiving or are planned to receive at least one medication with a metabolic pathway linked to genetic variations ("target drug").